

Special Issue

Targeted Therapies in Cardiovascular and Kidney Diseases

Message from the Guest Editors

Despite the various scientific and medical efforts invested into understanding the multitude of known kidney diseases, direct therapies to treat some of the most prevalent kidney disorders are yet to be identified. Furthermore, even though targeted therapies such as tyrosine kinase inhibitors, VEGF inhibitors, mTOR blockers and others are currently being used to tackle the progression of advanced kidney cancer, according to the American Cancer Society, these targeted therapies “Sometimes work when standard chemo drugs don’t”, but “it doesn’t seem that any of these drugs can actually cure kidney cancer”. Therefore, scientists have started focusing their research on the successful use of targeted therapies for kidney diseases, with multiple studies showing promise. In this Special Issue of *Pharmaceutics* on “Targeted Therapies in Kidney Diseases”, attempts to describe, discover and repurpose drug treatments for nephropathy, nephrotic syndrome, nephritic syndrome, CKD, AKI, polycystic kidney disease, Alport syndrome and kidney cancer will be highlighted.

Guest Editors

Dr. Assaad A. Eid

Prof. Dr. Koyo Nishida

Dr. Gene L. Bidwell, III

Dr. Rachel Njeim

Dr. Antony F. Haddad

Rashad Nawfal

Deadline for manuscript submissions

closed (20 August 2023)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/133516

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).